We postulated that this marker could be used to assess minimal residual disease (MRD) in T-lineage acute lymphoblastic leukemia (T-ALL). In diagnostic bone marrow (BM) samples from 27 children with T-ALL, expression of CD99 on leukemic lymphoblasts by flow cytometry was in median 7.7 times...
PI-MRD阳性状态与较短的EFS密切相关,中位值为21.6个月,而阴性患者则未达到。 信源:Tembhare PR, Narula G, Khanka T, et al. Post-induction Measurable Residual Disease Using Multicolor Flow Cytometry Is Strongly Predictive of Inferior Clinical Outcome in the Real-Life Management of Childhood T-Cell A...
2, 3, 4],用多色流式细胞术(multicolour flow cytometry,MFC)对r/r B-ALL患者进行骨髓微小残留病变(minimal residual disease,MRD)监测是重要预后变量,随着CD19-CAR-T细胞免疫治疗以及桥接移植在r/r
In some patients, the prognosis was evaluated based on prednisone response, MRD ysis, , age, white blood cell count, morphological and immunological subtypes and cytog ic change. Peripheral blood was obtained from patients and healthy volunteers. Informed consent was obtained from all patients in ...
Value of flow cytometry for MRD-based relapse prediction in B-cell precursor ALL in a multicenter setting Article Open access 14 December 2020 Analysis of measurable residual disease by IG/TR gene rearrangements: quality assurance and updated EuroMRD guidelines Article Open access 14 May 2024 ...
MRD was evaluated by flow cytometry and quantitative polymerase chain reaction was used to detect fusion genes; EMD was assessed using PET-CT, CT, or MRI. The median age was 22 (range, 2.3-55) years. Relapse was detected in the bone marrow in 21 (65.6%) pat...
Adult patients with confirmed CD19-positive, minimal residual disease (MRD)-positive, hematological or extramedullary r/r ALL received escalating doses of autologous T-lymphocytes retrovirally transduced with a third-generation CD19-directed CAR (RV-SFG.CD19.CD28.4-1BBzeta) [12]. Endpoints include...
10/47 cases had persistent positive minimal residual disease (MRD) per flow cytometry (FCM) after more than 3 cycle of chemotherapy, except one who had severe pneumonia after 1 cycle of chemotherapy. The MRD pre-treatment were ranging from 0.01%-1.53%. Chart 1: Characteristics of Patients ...
First, we assessed the clinical response of CNSL to CAR-T therapy in these patients. All patients with CNSL achieved CR approximately one to two weeks post CAR-T infusion (Fig.1a–c), accompanied by BM remission with MRD negative in patient 2 and patient 3 (Fig.1d). One month after ...
We postulated that this marker could be used to assess minimal residual disease (MRD) in T-lineage acute lymphoblastic leukemia (T-ALL). In diagnostic bone marrow (BM) samples from 27 children with T-ALL, expression of CD99 on leukemic lymphoblasts by flow cytometry was in m...